Review
Version 1
Preserved in Portico This version is not peer-reviewed
Targeting the Hippo Pathway in Melanoma
Version 1
: Received: 8 April 2024 / Approved: 8 April 2024 / Online: 9 April 2024 (08:52:48 CEST)
A peer-reviewed article of this Preprint also exists.
Kazimierczak, U.; Przybyla, A.; Smielowska, M.; Kolenda, T.; Mackiewicz, A. Targeting the Hippo Pathway in Cutaneous Melanoma. Cells 2024, 13, 1062. Kazimierczak, U.; Przybyla, A.; Smielowska, M.; Kolenda, T.; Mackiewicz, A. Targeting the Hippo Pathway in Cutaneous Melanoma. Cells 2024, 13, 1062.
Abstract
Melanoma is the most aggressive form of skin cancer. In the advanced stage of development it is resistant to currently available therapeutic modalities. Increased invasiveness and metastatic potential depend on a number of proteins involved in various signal transduction pathways. Hippo signaling plays an important role in malignant transformation. Dysfunctions of the Hippo pathway initiate the expression of tumor growth factors and is associated with tumor growth and metastasis formation. This review summarizes the recent achievements in studying the role of the Hippo pathway in melanoma pathogenesis and points to the potential specific targets for anti-melanoma therapy.
Keywords
Hippo signaling; melanoma; therapy
Subject
Biology and Life Sciences, Cell and Developmental Biology
Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Comments (0)
We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.
Leave a public commentSend a private comment to the author(s)
* All users must log in before leaving a comment